Title:
【発明の名称】TNFに対する抗体またはその誘導フラグメントおよびキサンチン誘導体の組み合わせ治療およびそのための組成物についての使用
Document Type and Number:
Japanese Patent JPH06502629
Kind Code:
A
Abstract:
A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy or prophylaxis of disorders associated with undesirably high levels of TNF, e.g. septic or endotoxic shock and immunoregulatory and inflammatory disorders, which comprises an antibody to TNF or a TNF binding fragment thereof and a xanthine derivative. Particular preferred xanthine derivatives are 3,7-dimethyl-1-(5-oxo-hexyl)xanthine (known as Pentoxifylline or Trental) and 1-(5-hydroxy-5-methylhexyl)-3-methylxanthine and similar compounds. The anti-TNF antibody or fragment is preferably monospecific especially a humanised recombinant antibody or fragment. The ratio of xanthine derivative to anti-TNF antibody component used may be in the range between 450:1 and 1:10 and doses of anti-TNF component in the range 0.001-30mg/kg/day and doses of xanthine derivative in the range 0.5 to 100mg/kg/day may be administered during treatment of human or animal subjects. It has been found that when an anti-TNF antibody and a xanthine derivative are used together in some experimental models of septic shock, a surprising combination effect is observed.
More Like This:
Inventors:
Anagnost Pros Hillist
Gerbert ulrich
Hanel Heinz
Limberto Michael
Bodmer Mark William
Higgs Gerald Anthony
Gerbert ulrich
Hanel Heinz
Limberto Michael
Bodmer Mark William
Higgs Gerald Anthony
Application Number:
JP51773591A
Publication Date:
March 24, 1994
Filing Date:
October 30, 1991
Export Citation:
Assignee:
Celtec Limited
Hoechst Actien Gezel Shaft
Hoechst Actien Gezel Shaft
International Classes:
A61K31/522; A61K39/395; A61P7/00; A61P29/00; A61P31/04; A61P37/00; A61P43/00; (IPC1-7): A61K39/395; A61K39/395
Attorney, Agent or Firm:
Makoto Kanesaka (1 person outside)